Urinary Retention Drug Market Report 2025

The urinary retention drug market size has grown strongly in recent years. It will grow from $3.87 billion in 2024 to $4.07 billion in 2025 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to an increase in the aging population, increasing healthcare investments and improvements in medical infrastructure, a growing geriatric demographic, a rising geriatric population across the globe, and an increasing prevalence of BPH.

The urinary retention drug market size is expected to see strong growth in the next few years. It will grow to $5.1 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to the increasing prevalence of urinary retention, rising incidence of postoperative urinary retention, increasing prevalence of urinary incontinence (UI), growing awareness about the benefits of early diagnosis and treatment, and increasing prevalence of benign prostatic hyperplasia. Major trends in the forecast period include targeted drug delivery systems, advances in drug formulations, artificial intelligence and machine learning, telemedicine and remote monitoring, and innovative solutions.

The forecast of 5.8% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade barriers may disrupt U.S. urology practices by increasing costs of selective alpha-blockers andbenign prostatic hyperplasia medications sourced from India and Israel, potentially delaying treatment for prostate-related voiding dysfunction and raising geriatric care expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing prevalence of urinary disorders is expected to fuel the expansion of the urinary retention drug market. Urinary disorders are conditions that affect the urinary system, leading to issues such as difficulty urinating, pain, incontinence, or retention. The rise in these disorders is largely due to the increasing incidence of diabetes, as elevated blood sugar levels can damage the kidneys and urinary tract, resulting in conditions such as diabetic nephropathy and frequent urinary tract infections (UTIs). Urinary retention drugs help manage these conditions by improving urine flow, relaxing bladder muscles, and alleviating symptoms such as difficulty urinating, thus enhancing comfort and bladder function. For example, in October 2023, the National Health Service (NHS) in England reported 147,285 hospital admissions in 2022/23 with a primary diagnosis of urinary tract infection (UTI). Among these cases, individuals over the age of 65 represented 56%, totaling 82,392 admissions, with the highest number of cases occurring in the 80-84 age group (17,280 cases). This increasing prevalence of urinary disorders is driving the growth of the urinary retention drug market.

Key players in the urinary retention drug market are focusing on the development of innovative formulations such as extended-release tablets to improve patient compliance and offer prolonged symptom relief. Extended-release (ER) tablets are designed to release the active ingredient gradually over time, maintaining a consistent drug concentration in the bloodstream and reducing the need for frequent dosing compared to immediate-release tablets. For instance, in April 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, launched a generic version of Mirabegron for overactive bladder (OAB). Mirabegron, a selective beta-3 adrenergic agonist, relaxes bladder muscles to reduce urinary urgency, frequency, and incontinence. Although primarily used for OAB, it can also assist in managing urinary retention linked to overactive bladder conditions. The medication is administered as a once-daily oral dose.

In November 2024, Boston Scientific Corporation, a healthcare company based in the U.S., acquired Axonics Inc. for $3.3 billion. This acquisition allows Boston Scientific to expand its urology portfolio by integrating innovative technologies that address urinary and bowel dysfunction. Axonics Inc., a medical technology company based in the U.S., specializes in sacral neuromodulation (SNM) therapy for urinary control. This therapy is used to treat urinary retention and the symptoms of overactive bladder.

Major players in the urinary retention drug market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc, Medtronic plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Lupin Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Ajanta Pharma Limited, Ferring Pharmaceuticals Inc., and UroGen Pharma Ltd.

North America was the largest region in the urinary retention drug market in 2024. The regions covered in urinary retention drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the urinary retention drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The urinary retention drugs market consist of sales of tamsulosin (flomax), bethanechol (urecholine), terazosin (hytrin), doxazosin (cardura), finasteride (proscar), and alfuzosin (uroxatral). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The urinary retention drug market research report is one of a series of new reports that provides urinary retention drug market statistics, including the urinary retention drug industry global market size, regional shares, competitors with the urinary retention drug market share, detailed urinary retention drug market segments, market trends, and opportunities, and any further data you may need to thrive in the urinary retention drug industry. This urinary retention drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Urinary retention drugs are medications used to treat conditions where patients experience difficulty emptying the bladder, often by relaxing the bladder muscles or stimulating contractions in the bladder to help urine flow. These drugs are commonly prescribed for conditions such as benign prostatic hyperplasia (BPH) or neurogenic bladder, aiming to improve urinary function and relieve discomfort.

The main drug classes for urinary retention include alpha blockers, beta-3 agonists, anticholinergics, and surgical agents. Alpha blockers are drugs that work by relaxing the bladder and prostate muscles, helping to improve urine flow and alleviate symptoms of BPH. These medications are used for conditions such as chronic urinary retention, postoperative urinary retention, and neurogenic bladder. They can be administered via oral, injectable, or transdermal routes and are prescribed in various settings, including hospitals, home care, specialty clinics, and others.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.